Our product pipeline includes ongoing human clinical trials for COVID-19 and advanced head and neck cancer. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors.
Our proprietary technology offers a well-validated platform approach that is suited for use against a wide range of cancers and infectious diseases with significant advantages versus competitive technologies. Our portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 115 granted or pending patent applications spread over 24 patent families.
Our business strategy is to advance our products through regulatory registration while also seeking partnership or licensing arrangements that might otherwise maximize the value to our shareholders. We also engage highly experienced third party resources/expertise through collaborations and partnerships for preclinical and clinical testing with well-validated industry, government, and other relevant entities.
